ClinicalTrials.gg
RecruitingNCT06422741CIRCAFENOLUpdated Aug 27, 2025

Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers

An interventional study of grape seed proanthocyanidin extract and Placebo in Cardiovascular Diseases, Circadian Rhythm Sleep Disorder, Shift Work Type and Cholesterol Level, High, sponsored by Fundació Eurecat. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Fundació Eurecat · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The physiological processes of the body present daily oscillations called circadian rhythm. The circadian rhythm is essential for maintaining the vital functions of organisms, intervening directly and indirectly in a multitude of key processes, such as hormone secretion, cycles of activity and rest throughout the day, body temperature, the metabolism or absorption, processing and detoxification of nutrients. There are factors such as certain work schedules, prolonged exposure to screens, certain eating patterns or social jetlag, which have a negative impact on the circadian rhythm, causing its disruption and favoring the appearance of health alterations. Thus, there is evidence that associates night shift work with a higher incidence of risk factors for developing metabolic syndrome and cardiovascular diseases, including obesity, elevated blood levels of glucose, triglycerides, and low-density lipoprotein cholesterol (LDL-C), as well as lower levels of high-density lipoprotein cholesterol (HDL-C). In addition, disorders in the sleep cycle are associated with the development of hypertension and type 2 diabetes.

Several previous studies show that a grape seed proanthocyanidin extract (GSPE) has beneficial effects on different parameters by restoring the circadian rhythm.

Read the detailed description

The main objective of the study is to evaluate the effect of daily GSPE intake, in combined with dietary recommendations, on LDL-C levels in individuals with rotating night shift work.

The secondary objectives are to evaluate the effects of GSPE on: anthropometric parameters,blood pressure, heart rate and endothelial function, markers of lipid and carbohydrate metabolism and insulin resistance, atherogenic indices, circulating levels of sex hormones and those related to hunger, satiety and stress; markers of systemic inflammation; circadian rhythm markers and sleep quality; level of physical activity, energy consumption, and changes in gene expression of key metabolic enzymes.

A randomized, crossover, placebo-controlled, triple-blind nutritional intervention study will be conducted. The study will be carried out in a population of 22 volunteers. Men and women aged 18 years or older, who are working a rotating night shift for at least 1 year and with blood levels of LDL-C between 116 and 190 mg/dL may participate.

Each volunteer will make 5 visits to the facilities of the EURECAT Nutrition and Health Technological Unit, in accordance with the study design:

  • A pre-selection visit (to check inclusion/exclusion criteria), and if the inclusion criteria are met.
  • Two study visits during consumption of the first product (GSPE or placebo), which will take place on the first day of study (visit 1) and after 6 weeks of treatment (visit 2).
  • Two study visits during consumption of the second product (GSPE or placebo), which will take place after a three-week washout period (visit 3), and after 6 weeks of treatment (visit 4).

The main variable of the CIRCAFENOL study is circulating LDL-C levels.

02

Conditions studied

  • Cardiovascular Diseases
  • Circadian Rhythm Sleep Disorder, Shift Work Type
  • Cholesterol Level, High

Keywords

  • Proanthocyanidins
  • Circadian Rhythm
  • Metabolic Syndrome
  • Melatonin
  • Polyphenols
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 22 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Fundació Eurecat is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years or older.
  • Follow a rotating night shift work schedule* for at least one year before the start of the study.

    * shift workers with at least 5 night shifts per month alternating with day and/or afternoon shifts, with a seniority equal to or greater than one year.

  • Have no intention of changing the work shift during the course of the study.
  • Circulating LDL-C levels between 116 -190 mg/dL*, without pharmacological treatment with antihypertensives and/or lipid-lowering agents.

    *Values of 116 to 190 mg/dl indicate moderate alteration in the lipid profile and a greater risk of suffering from cardiovascular diseases, according to the European Society of Cardiology, and the European Society of Atherosclerosis.

  • Have signed the before starting the study.
  • Know how to read, write and speak in Catalan or Spanish

Exclusion criteria

Exclusion Criteria:

  • values > 30 kg/m2
  • Take supplements, multivitamin supplements (Vit.D, Vit. E and Vit.C), mineral supplements (Zinc, Selenium), essential fatty acids (omega-3), polyphenols, natural plant extracts, or phytotherapeutic products that interfere with the treatment under study.
  • Consumption of alcoholic beverages:

    • Men: consume 4 or more Standard Beverage Units daily or 28 Standard Beverage Units weekly.
    • Women: Consume 2 or more Standard Beverage Units daily or 17 Standard Beverage Units weekly.
  • Be an active smoker.
  • Having lost more than 3 kg of weight in the last 3 months.
  • Present food intolerances and/or allergies related to the study products, such as to cellulose or proanthocyanidins.
  • Present any chronic or disease in clinical manifestation that may affect the results of the study such as diabetes (type I or II), cardiovascular disease, chronic kidney disease, hyper or hypothyroidism, chronic gastrointestinal diseases or cancer.
  • Present familial hypercholesterolemia.
  • Present hypertension (Systolic ≥140 mmHg; Diastolic ≥90 mmHg)
  • Present any previous cardiovascular disease defined as myocardial infarction, angina pectoris, stroke or peripheral arterial disease.
  • Individuals with treatment in the last 3 months before the start of the study with lipid-lowering, antidiabetic and/or antihypertensive drugs, or other drugs that may interfere with the results of the study.
  • Taking supplements with polyphenol components or those aimed at lipid or blood pressure control in the last 3 months before the start of the study or during participation in the study.
  • Follow a diet to lose weight, or very restrictive types of eating, such as intermittent fasting, ketogenic diet, etc.
  • Being pregnant or intending to become pregnant.
  • Being breastfeeding.
  • Be participating or have participated in a clinical trial with medications or nutritional intervention study in the last 30 days before inclusion in the study.
  • Suffering from eating disorders or psychiatric disorders.
  • Being unable to follow study guidelines.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    grape seed proanthocyanidin extract

    Participants will receive the grape seed proanthocyanidin extract (GSPE) for 6 weeks.

    Dietary Supplement: grape seed proanthocyanidin extract

  • Placebo comparator
    Placebo

    Participants will receive the placebo for 6 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementgrape seed proanthocyanidin extract

    250 mg of product presented in capsule form will be given.

  • Dietary supplementPlacebo

    165 mg of cellulose will be given presented in capsule form.

06

What researchers measure

Primary outcomes

  1. Change in LDL cholesterol levels.

    Serum LDL cholesterol levels will be measured by commercial colorimetric kit.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

Secondary outcomes

  1. Change in body weight.

    Body weight will be measured by standardized method.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  2. Height.

    Height will be measured by standardized method.

    Time frame: At week 1.

  3. Change in BMI.

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  4. Change in waist circumference.

    Waist circumference will be measured using a measuring tape.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  5. Change in conicity index.

    Weight, height and waist circumference will be combined to report Conicity index.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  6. Change in waist circumference to height ratio.

    Waist circumference and height will be combined to report Waist circumference to Height ratio.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  7. Change in the amount of body fat.

    Body fat will be measured by TANITA SC330.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  8. Change in the amount of muscle mass.

    Muscle mass will be measured by TANITA SC330.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  9. Change in the amount of bone mass.

    Bone mass will be measured by TANITA SC330.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  10. Change in the amount of total body water.

    Total body water will be measured by TANITA SC330.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  11. Change in systolic blood pressure.

    Systolic blood pressure will be measured using an automatic sphygmomanometer.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  12. Change in diastolic blood pressure.

    Diastolic blood pressure will be measured using an automatic sphygmomanometer.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  13. Change in resting heart rate.

    Resting heart rate will be measured using an automatic sphygmomanometer.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  14. Change in endothelial function.

    Endothelial function will be measured using the Laser-Doppler technique.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  15. Change in serum total cholesterol levels.

    Serum total cholesterol levels will be measured by standardized ultraviolet-visible spectrophotometry methods.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  16. Change in serum HDL-c levels.

    Serum HDL-c levels will be measured by standardized ultraviolet-visible spectrophotometry methods.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  17. Change in serum Triglycerides levels.

    Serum triglycerides levels will be measured by standardized ultraviolet-visible spectrophotometry methods.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  18. Change in total cholesterol to HDL-c ratio.

    Total cholesterol and HDL-c values will be combined to report Total cholesterol to HDL-c ratio.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  19. Change in LDL-c to HDL-c ratio.

    LDL-c and HDL-c values will be combined to report LDL-c to HDL-c ratio.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  20. Change in Plasma atherogenic index.

    Plasma atherogenic index will be calculated as the logarithm of the triglycerides levels to HDL-c levels ratio.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  21. Change in serum glucose levels.

    Serum glucose levels will be measured by standardized ultraviolet-visible spectrophotometry methods.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  22. Change in serum insulin levels.

    Serum insulin levels will be measured by spectrophotometry methods.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  23. Change in serum glycosylated hemoglobin levels.

    Serum glycosylated hemoglobin levels will be measured by commercial kits.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  24. Change in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR).

    HOMA-IR will be calculated using serum glucose and insulin levels.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  25. Change in serum high sensitivity c-reactive protein levels.

    Serum C-Reactive protein levels will be measured by plate test and by the agglutination of latex particles.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  26. Change in serum ghrelin levels.

    Serum ghrelin levels will be measured by ELISA kits.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  27. Change in serum leptin levels.

    Serum leptin levels will be measured by ELISA kits.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  28. Change in circulating thyroid hormone T3 levels.

    Serum T3 levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  29. Change in circulating thyroid hormone T4 levels.

    SerumT4 levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  30. Change in circulating testosterone levels.

    Serum testosterone levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  31. Change in circulating estrone levels.

    Serum estrone levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  32. Change in circulating 17-β-Estradiol levels.

    Serum 17-β-Estradiol levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  33. Change in circulating estriol levels.

    Serum estriol levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  34. Change in serum melatonin levels.

    Serum melatonin levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  35. Change in urine 6-Sulfatoxymelatonin levels.

    6-Sulfatoxymelatonin levels will be measured in spontaneous urine samples from two times of the day: morning and night by ELISA kit.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  36. Change in activity and rest cycles (subjective measurement).

    Activity and rest cycles will be measured subjectively by dream diaries. The sleep diary will be self-completed by the participant and will determine the time at which the person attempted to sleep, the duration and interruptions of nighttime sleep, the person's sleep pattern, and how much of the day the person was active.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  37. Change in activity and rest cycles (objective measurement).

    Activity and rest cycles will be measured objectively by actigraphs. The wrist actigraphs will be worn 24 hours a day and will measure heart rate, which will give an idea of the amount of time the person was asleep and active.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  38. Pittsburgh Sleep Quality Index.

    It is a validated scale that measures the usual sleep habits during the past month. It consist of 7 areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. It contains a total of 19 items, grouped into 10 questions where each of the areas evaluated is a scored between 0 and 3. The scores from the seven areas are finally added up to give an overall score. The component score are summed to produce a global score (range 0 to 21). Higher score indicate worse sleep quality.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  39. Chronotype.

    The chronotype will be evaluated using the Horne-Ostberg Morningness-Eveningness Questionnaire. Which consists of 19 questions that will allow volunteers to be classified into morning, night or intermediate people.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  40. Change in circulating GSPE metabolites.

    GSPE metabolites will be measured by LC-TQD-MS/MS.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  41. Change in food consumption habits.

    Food consumption will be evaluated through a 3-day food record.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  42. Change in Physical activity.

    Physical activity will be evaluated through the Physical Activity Questionnaire, Quick Physical Activity Classifier, adapted from the PEFS guide of the Generalitat de Catalunya. The questionnaire asks about three specific types of activity (walking, moderate-intensity activities and vigorous intensity activities) in the set domains leisure time, domestic and gardening (yard) activities, work-related and transport-related activities. Frequency and duration are collected separately for each specific type of activity.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  43. Change in body temperature.

    Body temperature will be measured using a infrared thermometer according to a standardized measurement protocol.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  44. Change in gene expression in peripheral blood mononuclear cells.

    The expression of key genes in lipid and carbohydrate metabolism and regulation of the circadian rhythm will be measured through transcriptomic analysis, performing RNA extraction, conversion to cDNA and subsequent analysis.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  45. Change in serum metabolite profile.

    serum metabolites will be determined by LC-TQD-MS/MS.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  46. Adverse events

    Possible adverse events derived from taking study's products will be recorded.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  47. Consumption of dietary supplements.

    Dietary supplements consumed during the study will be recorded in the case report form.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  48. Concomitant medication.

    Concomitant medication will be recorded in the case report form.

    Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).

  49. Age.

    Age will be recorded in years. It will be recorded in the case report form.

    Time frame: At week 1.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2026, 16 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 16 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
Oct 28, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06422741
Lead sponsor
Fundació Eurecat
Collaborators
University Rovira i Virgili
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Oct 28, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 27, 2025

Study contacts

Antoni Caimari Palou, PhD
Contact
antoni.caimari@eurecat.org
0034 977 300 805
Anna Crescenti, PhD
Contact
anna.crescenti@eurecat.org
0034 977 300 431
Antoni Caimari Palou, PhD
principal investigator · UTNS (Eurecat, Reus)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion